Is Fabino Enter overvalued or undervalued?

As of 16 September 2025, the valuation grade for Fabino Enter has moved from expensive to very expensive, indicating a significant shift in its market perception. The company is currently considered overvalued based on its financial metrics. Key ratios include a PE ratio of 5.35, an EV to EBIT of 6.75, and a ROE of 3.03%.
In comparison with peers, Fabino Enter's PE ratio of 5.35 is notably lower than Sun Pharma's 33.64 and Divi's Lab's 70, yet it remains classified as very expensive. The PEG ratio stands at 0.00, which is starkly lower than the average of its peers, suggesting a lack of growth expectations. Recent stock performance has also been underwhelming, with a year-to-date return of -22.55% compared to a positive 5.43% return from the Sensex, reinforcing the notion that the stock is overvalued in the current market environment.